Loading...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
ABV-press
2021-09-01
|
| Serier: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Fag: | |
| Online adgang: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|